Theratechnologies appoints new ceo

John-Michel Huss has more than 20 years’ experience in the pharmaceutical industry

Theratechnologies, a Canadian biopharmaceutical company based in Montreal, has appointed John-Michel Huss as president and chief executive.

Until recently, Huss was chief of staff, in the office of the ceo, at Sanofi-Aventis in Paris. He has more than 20 years’ experience in the pharmaceutical industry in various international positions and was responsible for various disease areas including diabetes and metabolism.

Huss began his career in 1990, at Merck & Co, primarily in sales and marketing in the US, Germany and Switzerland. In 1996, he was offered a position with F. Hoffman-La Roche as an internal product manager at its Basel headquarters in Switzerland. From there in 1999, he joined Sanofi-Synthélabo as business unit director and has held various positions of increasing responsibility in marketing and sales. He became general manager in Switzerland in 2007.

During his tenure at Sanofi-Aventis (Sanofi-Synthélabo merged with Aventis in 2004) Huss held positions in Germany, Canada, Switzerland and France.

‘I am honoured to have been chosen as Theratechnologies' president and ceo,’ said Huss.

‘The company has done an outstanding job of developing an exciting new compound, tesamorelin, and navigating it through the final regulatory stages of the drug development process.’

You may also like

Research & Development

Theratechnologies to cut 24 jobs in r&d restructure

Aims to strengthen its growth potential
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Subscribe now